Physician profile
David Feinstein
NPI 1609888965
$10,243.99
in general payments reported to CMS, 2019-2025
43 companies · $490 in 2025
The $490 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,286 · 2020: $5,005 · 2021: $911 · 2022: $658 · 2023: $477 · 2024: $416 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.05 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $4,434.55 | 2019-2020 | |
| Mannkind Corporation | $746.50 | 2019-2025 | Afrezza |
| Merz North America, INC. | $674.45 | 2019-2023 | |
| Novo Nordisk INC | $626.62 | 2019-2022 | |
| Allergan, INC. | $535.87 | 2019-2022 | |
| Insulet Corporation | $489.88 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $396.83 | 2019-2025 | |
| Abbvie INC. | $351.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $258.85 | 2019-2020 | |
| Abbott Laboratories | $166.49 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $163.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.78 | 2019-2025 | Jardiance |
| Dexcom, INC. | $116.66 | 2022-2025 | Dexcom G6 Transmitter |
| Valeritas, INC. | $109.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.16 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.